An extension study of phase 2 study of JR-142 in pediatric patients with growth hormone deficiency

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210366

Enrollment

Registered

2021-10-05

Start date

2021-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth hormone deficiency in children

Interventions

[Investigational product] JR-142 (INN: redalsomatropin alfa) 0.75 mg/kg/week or 0.5 mg/kg/week, weekly subcutaneous injection [Comparatar product] INN: Somatropin (genetical recombination) 0.175 mg/k

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A pediatric patient who completed the JR-142-201 study and was judged that there was no problem to participate in this study in terms of safety by principal investigator or sub investigator.

Exclusion criteria

Exclusion criteria: A pediatric patient with a diagnosis of diabetes (following the Diagnostic Procedure for Diabetes)

Design outcomes

Primary

Measure	Time frame
Change in height SDS for chronological age from baseline.	—

Contacts

Public ContactTsubasa Hirayama

JCR Pharmaceuticals Co., Ltd.

clinical_development@jp.jcrpharm.com+81-797-32-8582

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026